LAZCLUZE (Lazertinib) for EGFR-Mutated NSCLC: Uses, How It Works, and Key Facts

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, affecting over 200,000 people every year in the US [1]. For a long time, chemotherapy has been the main treatment, but it poses many serious side effects. 

Đọc thêm